This study aimed to detect the impact of inhaled Tranexamic acid® in pulmonary hemorrhage in pediatric intensive care unit.
Pulmonary hemorrhage, often manifested as hemoptysis, can be a severe and life-threatening condition. Tranexamic acid (TXA)® is a lysine analog that prevents the conversion of plasminogen to plasmin and inhibits plasmin's binding to fibrin, stabilizing the fibrin matrix and reducing bleeding.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Patients received inhaled or endotracheally instilled Tranexamic acid (TXA) in addition to conventional therapy.
Patients received conventional systemic Tranexamic acid (TXA) alone.
Tanta University
Tanta, El-Gharbia, Egypt
Cessation of pulmonary hemorrhage
The cessation of pulmonary hemorrhage within 48 hours of starting inhaled tranexamic acid was recorded.
Time frame: 48 hours of starting inhaled tranexamic acid
Incidence of adverse effects
Incidence of adverse effects was recorded.
Time frame: 48 hours of starting inhaled tranexamic acid
In-hospital mortality
Incidence of in-hospital mortality was recorded.
Time frame: 48 hours of starting inhaled tranexamic acid
Length of hospital stay
Length of hospital stay was recorded from the admission till the discharge from the hospital.
Time frame: Till the discharge from the hospital (Up to 2 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.